Acs Fall 2024 Vvd-130037 Vvd1300372. (vividion), announced today that it has initiated dosing of patients in a. Technical sessions, networking, career development & more.
(vividion), announced today that it has initiated dosing of patients in a. Vividion has already disclosed work on covalent keap1 inhibitors, but at the recent acs fall 2024 meeting, the structure and discovery story of their clinical oral covalent.
Acs Fall 2024 Vvd-130037 Vvd1300372 Images References :